Abstract

The formation of amyloid β (Aβ) fibrils is considered one of the key triggers of Alzheimer’s disease (AD). Molecules able to inhibit the Aβ fibrillation and/or to disrupt mature fibrils are thus promising for the prevention and treatment of AD. In this study, the anti-amyloidogenic activity of vitamin B12 (VB12) was investigated by following kinetic studies. Evidence demonstrated that VB12 slows down the Aβ aggregation process and reduce the content of fibrils. Additionally, the vitamin exhibited a strong ability in disaggregating fibrils. These findings suggest that VB12 could be explored as a promising compound for AD therapy.